Vinblastine-RICHTER

Active material: Vynblastyn
When ATH: L01CA01
CCF: Anticancer drug
When CSF: 22.03.01
Manufacturer: GEDEON RICHTER Ltd. (Hungary)

Pharmaceutical form, composition and packaging

Lyophylisate dlya solution for the on/in the introduction white or yellowish white.

Solvent: 0.9% rr sodium chloride – 5 ml.

Dark glass bottles (10) together with the solvent (amp. 10 PC.) – packs cardboard.

DESCRIPTION OF ACTIVE SUBSTANCES.

Pharmacological action

The antitumor agent. The mechanism of action is related to the blockade of tubulin and stopping cell division in metafaze.

Pharmacokinetics

Marginally GEB. Plasma protein binding is 75%. Biotransformiroetsa in the liver with the formation of active metabolites. Mostly appears to jelchew, partially – kidney.

Testimony

Limfogranulematoz, non-Hodgkin's lymphoma, germinoguenne testicular tumors and ovarian cancer, xoriokarцinoma (rezistentnaya to other chemotherapeutic drugs), Kaposi's sarcoma, granulosarcoid (severe), disease Letterera-Siva, kidney cancer, bladder cancer, sympathicoblastoma, nasopharyngeal cancer, lung cancer, mammary cancer.

Dosage regimen

Establish individually, depending on the evidence and disease stage, the state of the hematopoietic system, scheme anticancer therapy.

Side effect

From the central and peripheral nervous system: Neuropathy, Neuritis of peripheral nerves, headache, depression, convulsions.

From the hematopoietic system: leukopenia, granulocytopenia, thrombocytopenia, anemia.

From the digestive system: anorexia, nausea, vomiting, stomach ache, pseudoileus, constipation, diarrhea, ulcerative stomatitis, hemorrhagic enterocolitis.

Cardio-vascular system: increased blood pressure, myocardial infarction, cerebrovascular accidents, increased exposure to illness Reynaud.

The respiratory system: acute respiratory failure, bronchospasm.

Reproductive system: azoospermia, amenorrhea.

Other: alopecia, ostealgias.

Contraindications

Expressed lakopenia, pregnancy, hypersensitivity to vinblastinu.

Pregnancy and lactation

Vinblastine is contraindicated for use in pregnancy. If necessary, the use of lactation should stop breastfeeding.

When applying for women of childbearing age are recommended to use reliable methods of contraception.

IN experimental studies installed teratogenic effects of vinblastine.

Cautions

Be wary vinblastine in patients with chicken pox (incl. recently transferred or after contact with sick), Herpes Zoster, other acute infectious diseases, gout, nefrolitiazom (incl. history). In patients with impaired liver function, elevated the risk of toxic effects of vinblastine.

To apply caution in the face of treatment drugs, oppressive izofermenta CYP3A activity.

Maximum depression of blood (primarily the reduction in the number of leukocytes in peripheral blood) achieved through 5-10 days after discontinuation of vinblastine. Normalization of the number of cells in the peripheral blood is a 7-14 days. Development of thrombocytopenia (less 200 000/l) most likely in patients, receiving prior anti-tumor or radiation therapy. Normalization of the number of platelets is celebrated, usually, a few days after the lifting of vinblastine.

The risk of radiation in the application of vinblastine in patients with elevated kahexiei and ulcerous lesions of skin, Therefore, patients with the above States to appoint does not recommend. In patients with metastases in bone marrow marked falls in the number of leukocytes and platelets was observed after the application of vinblastine in medium doses. In these cases, the continued application of vinblastine not shown.

During therapy should monitor activity transaminaz liver and LDH, levels of bilirubin and uric acid concentrations in blood plasma.

During treatment is not recommended vaccination of patients and their families.

Vnutriobolocherne introduction of vinblastine may cause fatal. In case of accidental contact with eyes may arise a strong inflammation.

Drug Interactions

Together with the application activity inhibitors izofermenta CYP3A may earlier emergence and/or exacerbation of severity of the side effects of vinblastine.

Together with the application of vinblastine may reduce concentration fenitoina plasma and decrease its anticonvulsant activity, apparently, by reducing the absorption of, improve the speed of metabolism and elimination of fenitoina.

While the application of vinblastine in high doses with interferon alfa-n1 possible severe mielodeprescia.